Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study

Authors
Category Primary study
JournalBlood
Year 2023
This article has no abstract
Epistemonikos ID: 29d483a85fa92cbe1691a0c9c582065aa7050684
First added on: Feb 17, 2025